Coalition to Cure Calpain 3 is dedicated to advancing scientific and clinical research to find effective treatments and, ultimately, a cure for calpainopathy (LGMD2A/R1 and LGMDD4).
Led by Scientific Director Dr. Jennifer Levy, the C3 grant program funds world-renowned scientists and clinicians to ultimately bring promising work to clinical trials for the calpainopathy community. Our Scientific Advisory Board works with Dr. Levy in evaluating grant proposals focused on potential therapeutic approaches, such as gene therapy, gene editing, and non-genetic drug therapies.
Additionally, C3 is investing in developing a “toolbox” of essential building blocks for scientists to conduct research on calpainopathy and for pharmaceutical companies to be able to conduct clinical trials in the disease. These initiatives — tool creation and clinical trial readiness — include a patient registry, natural history studies and outcome measures, animal models, and fundamental research on the biology of LGMD2A/R1 and LGMDD4.